Key Insights from Attending ASH 2025

Key Insights from Attending ASH 2025

From Treating Blood Cancers by Blood Cancer United

January 13, 2026 · 34 min

About this episode

Dr. Lore Gruenbaum discusses key insights and breakthroughs in blood cancers from the ASH 2025 Annual Meeting.

Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC Recorded on December 18, 2025 Lore Gruenbaum, PhD Chief Scientific Officer & Senior Vice President of Research Blood Cancer United Washington, DC Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

People in this episode

Guest: Lore Gruenbaum Phd

Topics covered

  • hematologic malignancies
  • multiple myeloma
  • AML
  • CLL
  • cell therapy
  • artificial intelligence
  • precision medicine

Keywords

  • ASH 2025
  • Blood Cancer United
  • Beat AML® Master Clinical Trial
  • clinical decision-making

Mentioned in this episode

Places: Washington, DC

More episodes of Treating Blood Cancers

Explore listener stats, chart rankings, contacts and more on the Treating Blood Cancers podcast page.